<DOC>
	<DOCNO>NCT02603068</DOCNO>
	<brief_summary>This multicenter , randomize , open-label study ass safety efficacy oral treprostinil subject diagnose pulmonary hypertension associate pulmonary fibrosis .</brief_summary>
	<brief_title>Oral Treprostinil Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis</brief_title>
	<detailed_description>This study evaluate oral treprostinil affect pulmonary vascular resistance , assess right heart catheterization , exercise capacity , assess Six-Minute Walk Test . This 16-week study involve least 10 clinical trial center . The expected enrollment period around 24 month 52 subject enter study .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Voluntarily give informed consent Must meet criterion lung transplant referral require active lung transplant list Stable significant diffuse parenchymal lung disease diagnosis interstitial lung disease 6MWD great equal 75 meter Right heart catheterization mean pulmonary arterial pressure &gt; = 30 mgHg , pulmonary capillary wedge pressure &lt; = 15 mmHg pulmonary vascular resistance &gt; 240 dyne EchoDoppler examination show evidence right ventricular dysfunction normal leave diastolic ventricular function Either receive PAHapproved oral therapy , receive monotherapy ( ERA , PDE5I , riociguat ) &gt; 60 day receive stable dose &gt; 30 day prior enrollment Able communicate effectively study personnel cooperative protocol requirement History repair unrepaired congenital heart disease Received prostanoid therapy past 30 day , show intolerance lack efficacy prostanoid therapy result discontinuation inability titrate prostacyclins Diagnosis sarcoidosis History thromboembolic disease Chronic renal insufficiency Pregnancy lactate Currently receive investigational drug , investigational device place , participate investigational drug device study within 30 day prior Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>